Coronavirus disease 2019 (COVID-19)

History and recognition

SARS-CoV-2 was identified following clusters of atypical pneumonia reported in late 2019. Early investigations established a new coronavirus as the causative agent, and the disease it causes was named COVID-19. As the pathogen spread globally, coordinated efforts in laboratory science, epidemiology and clinical medicine sought to characterize transmission dynamics, risk factors for severe disease, and effective prevention and treatment strategies. International sharing of genomic, clinical and epidemiological data became a major feature of the response.

Transmission

Transmission occurs primarily by respiratory routes. Virus-containing droplets and smaller aerosol particles produced when infected people breathe, speak, sing, cough or sneeze can be inhaled by others, especially during prolonged contact in indoor or poorly ventilated spaces. Direct close contact, including via large droplets, and short-range airborne exposure are important modes. Transmission via contaminated surfaces (fomites) is possible but generally regarded as a smaller contributor to spread than airborne transmission. Occasional events in which a single infected person infects many others—so-called superspreading events—have significantly amplified outbreaks in some settings.

Incubation period and contagiousness

The incubation period is typically a few days, with many people developing symptoms within about a week of exposure; a minority develop symptoms later. Individuals may be infectious before they develop symptoms (presymptomatic transmission) and some who never develop symptoms (asymptomatic) can also transmit the virus. Viral shedding dynamics, host factors and behavior influence contagiousness; these features complicate containment measures that rely on identifying symptomatic cases alone.

Clinical features

Clinical manifestations range from no symptoms to mild respiratory illness and to severe disease requiring hospitalization. Common early symptoms include fever, new persistent cough, fatigue and breathlessness. Other frequently reported signs are sore throat, nasal congestion, muscle aches, headache, gastrointestinal symptoms such as nausea or diarrhea, and changes in taste or smell. Severity ranges from mild upper respiratory illness to pneumonia, hypoxaemia and acute respiratory distress syndrome in more severe cases. Complications can affect the heart, kidneys, liver, nervous system and coagulation pathways.

Risk factors for severe disease

The probability of severe illness increases with older age and with certain underlying medical conditions. Chronic cardiovascular disease, diabetes, chronic respiratory disease, obesity, immunosuppression and other chronic disorders have been associated with higher risk of hospitalization and adverse outcomes. However, severe and prolonged illness can also occur in younger and previously healthy people, and pregnancy has been associated with increased risk of severe disease in some studies. Risk assessment for individuals should be made considering current evidence and clinical judgment.

Long-term effects and post-acute sequelae

A proportion of people experience persistent or new symptoms for weeks to months after the acute infection, a condition commonly referred to as Long COVID or post-acute sequelae of SARS-CoV-2 infection. Reported problems include ongoing fatigue, breathlessness, cognitive difficulties ('brain fog'), chest pain, palpitations, sleep disturbance and a range of other physical and psychological symptoms. The prevalence, mechanisms and optimal management of these long-term effects remain active areas of research.

Diagnosis

Diagnosis of acute infection is based primarily on tests that detect the virus. Nucleic acid amplification tests (NAATs), such as reverse transcription polymerase chain reaction (RT-PCR), detect viral genetic material from respiratory specimens and are highly sensitive for active infection when properly performed. Antigen tests detect viral proteins, often providing faster results and used for screening and point-of-care testing, though they are typically less sensitive than molecular assays. Serological tests detect antibodies and can indicate prior infection or immune response after vaccination but are not reliable for diagnosing acute infection on their own.

Treatment and clinical management

Management depends on severity. Most people with mild illness receive supportive care at home, including rest, hydration and symptom control, and are advised on isolation to prevent onward transmission. Hospitalized patients may require supplemental oxygen, monitoring and treatment of complications. Evidence-based therapies for patients with moderate to severe COVID-19 have included systemic corticosteroids to reduce harmful inflammation in certain hospitalized patients, antiviral agents in selected settings, and targeted immunomodulatory drugs for patients with specific inflammatory profiles. Clinical guidelines have evolved as trials and observational studies refined understanding of benefits and harms.

Prevention and nonpharmaceutical measures

Measures to reduce transmission include improving ventilation of indoor spaces, maintaining physical distance where appropriate, limiting time spent in crowded settings, respiratory etiquette, hand hygiene and the use of well-fitting masks in high-risk circumstances. Testing, case isolation, contact tracing and quarantine of exposed persons are standard public-health tools. The combination and intensity of nonpharmaceutical interventions vary by epidemiological situation, health-system capacity and policy objectives.

Vaccination

Vaccines against SARS-CoV-2 were developed and deployed at an unprecedented pace using multiple technological platforms, including mRNA, viral vectors, protein subunits and inactivated virus. Vaccination has been shown to reduce the risk of severe illness, hospitalization and death, and to contribute to population-level control of disease when coverage is high. Vaccine effectiveness against infection and transmission can change with time since vaccination and with the emergence of viral variants; booster doses and updated vaccine formulations have been used in some settings to maintain protection, particularly for high-risk groups.

Variants and viral evolution

SARS-CoV-2 mutates over time as it replicates and spreads. Most genetic changes have little or no impact on virus properties, but some variants alter transmissibility, disease severity or the ability to evade immune responses. Public-health authorities and researchers monitor genetic changes through genomic surveillance to identify variants of interest or concern. Decisions about diagnostics, treatments and vaccines take into account the characteristics of currently circulating variants and their potential public-health impact.

Testing, surveillance and public-health response

Ongoing surveillance combines clinical reporting, laboratory testing and genomic sequencing to track transmission, detect changes in disease patterns, and inform public-health measures. Surveillance systems also monitor healthcare burden, vaccination coverage and outcomes. National and international collaboration supports data sharing and coordinated responses, while differences in testing capacity, reporting practices and healthcare infrastructure influence the completeness and comparability of data between locations.

Social, economic and ethical considerations

The pandemic has had wide-ranging effects on healthcare systems, education, employment and social life. Measures to control transmission have trade-offs, affecting mental health, economic activity and access to services. Equitable access to tests, treatments and vaccines has been a major ethical and practical concern, as has the protection of vulnerable populations and the balancing of individual liberties with collective health. Preparedness, communication, and trust between communities and authorities are important determinants of effective public-health action.

Research and ongoing questions

Research remains active across many domains: improved diagnostics, treatments and vaccines; understanding mechanisms of severe disease and long-term sequelae; the duration of immunity after infection or vaccination; and optimal public-health strategies for prevention and mitigation. Rapid dissemination of findings, including through preprints and peer-reviewed publications, has accelerated knowledge but also requires careful evaluation of study quality. As evidence accumulates, recommendations are updated to reflect best available information.

Practical advice and sources of guidance

• Individuals should follow current local public-health guidance on testing, isolation, vaccination and prevention measures.
• People with symptoms consistent with COVID-19 or with known exposure should seek testing and advice from health services as recommended in their area.
• Vaccination remains a central tool to reduce severe outcomes; eligibility, schedules and booster recommendations differ by jurisdiction and over time.

Because SARS-CoV-2 and COVID-19 are relatively recent and the evidence base continues to grow, recommendations and knowledge may change. For the latest, locally relevant information consult official public-health authorities and peer-reviewed scientific sources. This article summarizes broadly accepted aspects of the disease and response without exhaustive detail on jurisdiction-specific policies or rapidly changing data.